Dudediligence.

Syndax Pharmaceuticals, Inc

SNDXNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$12.5MSep ’24$7.7MDec ’24$20.0MMar ’25$38.0MJun ’25$45.9MSep ’25$68.7MDec ’25$64.9MMar ’26$72.8MJun ’26
Net income, by quarter
−$84.1MSep ’24−$94.2MDec ’24−$84.8MMar ’25−$71.8MJun ’25−$60.7MSep ’25−$68.0MDec ’25−$42.7MMar ’26−$49.4MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$139.7M$0.00$0.00$23.7M$172.4M
Operating income$26.2M−$151.8M−$230.0M−$339.7M−$273.1M
Net income$24.9M−$149.3M−$209.4M−$318.8M−$285.4M
Operating cash flow$29.1M−$133.7M−$160.6M−$274.9M−$323.0M
Free cash flow$29.0M−$133.7M−$160.6M−$274.9M−$323.2M
Cash$222.0M$74.4M$295.4M$154.1M$134.9M
Debtnone on filenone on file$0.00$343.7M$343.9M
Shares outstanding55.0M68.1M84.8M85.7M87.4M